RDHL — RedHill Biopharma Ltd.
—
Nasdaq ·
Health Care ·
Pharmaceuticals ·
CIK 1553846 ·
Last close
$0.65
Market Cap
$3.95M
52W High
$1.10
52W Low
$0.63
ADV30
90,583
Next earnings
—
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | GrossProfit | OpIncome | NetIncome | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Dec 2025 | — | — | — | — | 25,345,000 | 3,971,000 | 21,077,000 |
| Jun 2025 | — | — | — | — | — | 2,866,000 | — |
| Dec 2024 | — | — | — | — | 18,043,000 | 4,617,000 | 22,726,000 |
Balance + Analyst (yfinance extras)
Retained Earnings
$-413,755,000
Inventory
$0
Receivables
$2,479,000
ST Investments
—
EBIT TTM
—
Pretax Income TTM
—
Interest Exp TTM
—
Analysts
—
Yahoo Snapshot (yfinance, live)
Total Revenue
$286,000
EBITDA
$-7,793,000
Free Cash Flow
$-2,176,000
Enterprise Value
$409,011
Total Cash
$3,971,000
Total Debt
$1,070,000
Shares Out
6,080,920
Trailing EPS
$0.00
Book Value
$0.84
ROE
—
ROA
-22.8%
Div Yield
—
Annual Trend (SEC EDGAR, last 5y)
Revenues vs Net Income (last 5y)
| FY end | Revenues | OpIncome | NetIncome | Assets | Liabilities | Equity | OCF |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 286,000 | -7,909,000 | -429,000 | 25,345,000 | 21,077,000 | — | -9,651,000 |
| Dec 2024 | 0 | -6,475,000 | -8,268,000 | 18,043,000 | 22,726,000 | — | -9,369,000 |
| Dec 2023 | 0 | -9,547,000 | 23,916,000 | 23,047,000 | 20,978,000 | — | -35,820,000 |
| Dec 2022 | 61,800,000 | -42,844,000 | -71,669,000 | 158,870,000 | 207,270,000 | — | -29,185,000 |
| Dec 2021 | — | — | — | — | — | — | — |
TTM Snapshot
Revenues TTM
—
NetIncome TTM
—
OpCashFlow TTM
—
Assets (Latest)
—
Forward EPS
$0.03
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| ENSC | Ensysce Biosciences, Inc. | $3.89M | $0.25 | — |
| CTTH | CTT PHARMACEUTICAL HOLDINGS, INC. | $3.87M | $0.07 | — |
| MBIO | MUSTANG BIO, INC. | $3.84M | $0.57 | — |
| CVSI | CV Sciences, Inc. | $4.08M | $0.02 | — |
| SPRC | SciSparc Ltd. | $4.08M | $7.12 | — |
News headlines (Yahoo Finance, 1h cache)
Inflammatory Bowel Disease Market to Experience Strong Uptake During the Forecast Period (2026-2036), Driven by Development of Next-generation Therapies Targeting IL-23, TL1A, and S1P Pathways | Delve
2026-07-30 14:31 · Yahoo
Ebola Cases and Deaths Rapidly Mount - RedHill Updates on Opaganib Emergency Outbreak Development
2026-07-28 11:00 · Yahoo
RedHill Biopharma Announces Closing of Up To $19.4 Million Private Placement
2026-06-22 20:10 · Yahoo
RedHill Biopharma Announces Up To $19.4 Million Private Placement
2026-06-18 12:00 · Yahoo
RedHill's Opaganib Receives FDA Rare Pediatric Disease Designation for Neuroblastoma in Addition to Current Orphan Drug Designation
2026-06-09 11:00 · Yahoo
RedHill Launches Enforcement of $11 Million New York Supreme Court Final Judgment Against Kukbo
2026-06-08 11:00 · Yahoo
RedHill Biopharma Advancing Opaganib Options for Novel Dual Host Directed and Direct Acting Antiviral Approach for Ebola Outbreak Biodefense Platforms
2026-06-02 12:00 · Yahoo
RedHill's RHB-204 Demonstrates Comparable MAP Killing Efficacy to RHB-104 - Important Step in RHB-204 Development for MAP-related Crohn's Disease
2026-04-30 11:00 · Yahoo
RedHill Biopharma Announces Full-Year 2025 Financial Results and Operational Highlights
2026-04-27 12:00 · Yahoo
RedHill's Opaganib Enhances Efficacy of Neuroblastoma Chemo Combination and Augment Anti-Tumor Immunity in Triple-Negative Breast Cancer in Preclinical Studies - New Data Presented at AACR 2026
2026-04-22 12:00 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.